The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

November 23, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—The COVID-19 pandemic has radically altered the landscape of medicine across the U.S. and the world. A great deal of research has been, and is being, conducted to understand the SARS-CoV-2 virus and its implications for all fields of medicine; the rheumatology specialty is no exception. In fact, new concepts in autoimmunity and immunology are being discovered every day, shifting paradigms of how we understand the balance between disease and health. On Nov. 4, experts came together to discuss the implications for rheumatology.

You Might Also Like
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Research Helps Explain Idiosyncrasies of COVID-19
  • After COVID-19-Associated MIS-C, Immune Changes Resolve
Also By This Author
  • Without Fear: Psychological Safety for Learners & Patients

Dr. Krause

FDA View

Philip Krause, MD, deputy director of the Office of Vaccines Research and Review at the U.S. Food & Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Silver Spring, Md., began the session by providing an overview of hot topics related to COVID-19 vaccines and regulation. He noted that the FDA has played a key role in evaluating the safety and efficacy of vaccines against SARS-CoV-2 and, in the process, has had to balance competing goals.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Specifically, the FDA has sought to adhere to a rigorous, evidence-based approach for its scientific review, which can be slow and tedious, while aiming to quickly make vaccines widely available to a public in dire need of protection from the virus. Dr. Krause noted that emergency use authorization (EUA) helps balance these issues. Under EUA, the FDA can permit the use of unapproved medical products, such as vaccines, in times of emergency so long as certain statutory criteria have been met, including that no adequate, approved and available alternatives exist.

Dr. Krause explained that severe side effects related to vaccines have been quite rare and that certain specific adverse events, such as myocarditis or pericarditis, appear to have the highest incidence after the second dose of the mRNA vaccines. Further, data are still unclear regarding the efficacy of providing booster vaccination doses to the general population. Although a booster dose is clearly indicated for immunocompromised patients and those with the highest risk for SARS-CoV-2 infection, what should be done for young, healthy individuals? Should society wait for variant-specific boosters to become available for administration? How well and for how long will booster doses protect against transmission of SARS-CoV-2?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Many questions remain and may take years of research to answer.

Anti-Vaccine Sentiment

The session’s next speaker was Peter Hotez, MD, PhD, dean of the National School of Tropical Medicine, Baylor College of Medicine, Houston. Dr. Hotez discussed, among other things, the three phases of anti-vaccine sentiment that have swept across the U.S. over the past several decades.

Pages: 1 2 3 4 5 6 7 8 9 | Single Page

Filed Under: ACR Convergence, Meeting Reports Tagged With: ACR Convergence 2021, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), U.S. Food and Drug Administration (FDA), vaccine hesitancy

You Might Also Like:
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Research Helps Explain Idiosyncrasies of COVID-19
  • After COVID-19-Associated MIS-C, Immune Changes Resolve
  • Basic Science: New Insights into Inflammation in OA, VEXAS, COVID-19 & More

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)